A Precision-Oncology Bet With Room to Grow
Eli Lilly and Company (NYSE: LLY) is adding another potential growth engine to a business already well acquainted with acceleration. On November 16, Calytrix Bio announced a definitive agreement to be acquired by Lilly in…
Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…
The market’s most investable theme today is not simply artificial intelligence, healthcare or macroeconomics in isolation. It is possibly the increasingly visible convergence of all three: businesses finding ways to monetize AI, healthcare platforms turning operational discipline into financial leverage, and policymakers…
